These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6414088)

  • 21. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis.
    Stinnett AA; Mullahy J
    Med Decis Making; 1998; 18(2 Suppl):S68-80. PubMed ID: 9566468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.
    Willan AR; O'Brien BJ
    Health Econ; 1996; 5(4):297-305. PubMed ID: 8880166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?
    Eichler HG; Kong SX; Gerth WC; Mavros P; Jönsson B
    Value Health; 2004; 7(5):518-28. PubMed ID: 15367247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CE plane: a graphic representation of cost-effectiveness.
    Black WC
    Med Decis Making; 1990; 10(3):212-4. PubMed ID: 2115096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using cost-effectiveness analysis for formulary decision making: from theory into practice.
    Detsky AS
    Pharmacoeconomics; 1994 Oct; 6(4):281-8. PubMed ID: 10147465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
    Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
    J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs.
    Posnett J; Jan S
    Health Econ; 1996; 5(1):13-23. PubMed ID: 8653189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness and the allocation of therapies in a treating population.
    Langley PC
    Pharmacoeconomics; 1996 Jul; 10(1):93-8. PubMed ID: 10160473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis.
    Robinson R
    BMJ; 1993 Sep; 307(6907):793-5. PubMed ID: 8219957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of a group-based exercise program for falls prevention among the older community-dwelling population.
    McLean K; Day L; Dalton A
    BMC Geriatr; 2015 Mar; 15():33. PubMed ID: 25879871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness league tables: valuable guidance for decision makers?
    Mauskopf J; Rutten F; Schonfeld W
    Pharmacoeconomics; 2003; 21(14):991-1000. PubMed ID: 13129413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of family planning programs in rural Bangladesh: evidence from Matlab.
    Simmons GB; Balk D; Faiz KK
    Stud Fam Plann; 1991; 22(2):83-101. PubMed ID: 1907039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis and insurance coverage: solving a puzzle.
    Pauly M
    Health Econ; 2015 May; 24(5):506-15. PubMed ID: 24677289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the cost-effectiveness of clinical and public health measures.
    Graham JD; Corso PS; Morris JM; Segui-Gomez M; Weinstein MC
    Annu Rev Public Health; 1998; 19():125-52. PubMed ID: 9611615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness and Budget Impact of Specialized Psychotherapy for Borderline Personality Disorder: A Synthesis of the Evidence.
    Wetzelaer P; Lokkerbo J; Arntz A; van Aselt T; Smit F; Evers S
    J Ment Health Policy Econ; 2017 Dec; 20(4):177-190. PubMed ID: 29300704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.